LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO)
| dc.contributor.author | Tran, N. | |
| dc.contributor.author | Ozguroglu, M. | |
| dc.contributor.author | Sulur, G. | |
| dc.contributor.author | Protheroe, A. | |
| dc.contributor.author | Li, S. | |
| dc.contributor.author | Mundle, S. D. | |
| dc.contributor.author | Chi, K. N. | |
| dc.contributor.author | Rodriguez Antolin, A. | |
| dc.contributor.author | Feyerabend, S. | |
| dc.contributor.author | Fein, L. | |
| dc.contributor.author | Alekseev, B. Y. | |
| dc.contributor.author | De Porre, P. | |
| dc.contributor.author | Matsubara, N. | |
| dc.contributor.author | Fazazi, K. | |
| dc.date.accessioned | 2021-03-05T14:35:37Z | |
| dc.date.available | 2021-03-05T14:35:37Z | |
| dc.identifier.citation | Matsubara N., Chi K. N. , Ozguroglu M., Rodriguez Antolin A., Feyerabend S., Fein L., Alekseev B. Y. , Sulur G., Protheroe A., Li S., et al., "LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO)", 43rd ESMO Congress (ESMO), Munich, Almanya, 19 - 23 Ekim 2018, cilt.29 | |
| dc.identifier.other | av_b7e5e76c-8656-4c31-b7d5-969bd243e9ca | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/122369 | |
| dc.language.iso | eng | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Tıp | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Onkoloji | |
| dc.subject | ONKOLOJİ | |
| dc.subject | Klinik Tıp | |
| dc.title | LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO) | |
| dc.type | Bildiri | |
| dc.contributor.department | National Cancer Center - Japan , , | |
| dc.identifier.volume | 29 | |
| dc.contributor.firstauthorID | 154950 |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||
This item appears in the following Collection(s)
-
Bildiri [64839]